Completed
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
NCT00848055
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, +1 more
- Locations
-
- 1240.1.05 Boehringer Ingelheim Investigational Site Boise, Idaho, United States
- 1240.1.06 Boehringer Ingelheim Investigational Site Evansville, Indiana, United States
- 1240.1.04 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States
- 1240.1.02 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States